New advances of epigenetic study in tumors of lymphatic system---review.
- Author:
Yan-Li LI
1
;
Zhi-Min ZHAI
Author Information
1. Department of Hematology, Anhui Medical University Second Hospital, Hefei, Anhui Province, China.
- Publication Type:Journal Article
- MeSH:
Amino Acid Motifs;
DNA Methylation;
Epigenesis, Genetic;
Histones;
genetics;
Humans;
Lymphatic Diseases;
genetics;
Lymphatic System;
Neoplasms;
genetics
- From:
Journal of Experimental Hematology
2012;20(1):219-223
- CountryChina
- Language:Chinese
-
Abstract:
Epigenetics is aimed to study the heritable changes in gene expression patterns independent of alterations in genomic DNA sequence structure, and the mechanisms of translation from genotype to phenotype. In recent years, compelling evidence gathered supports a role of epigenetic alterations in the pathogenesis of lymphatic system tumors. For example, recent data from multiple laboratories indicate that several hundred genes, involving dozens of critical molecular pathways, are epigenetically suppressed in acute lymphocytic leukemia; a panel of methylation markers can be used for additional risk stratification of chronic lymphocytic leukemia patients; based on the epigenetic profiles, the class prediction models in gray zone lymphoma can be established; the epigenetic silencing of microRNAs in multiple myeloma generally appears to have intact P53 function; epigenetic therapies have broader implication and high potential for the development of immunotherapeutic strategies and so on. In this review, the latest advances of epigenetic study and the prospect of epigenetic therapy for tumors in lymphatic system are summarized.
